Company / PP&E (Net)
Ernexa Therapeutics Inc. PP&E (Net) History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$94.0K
FY2025
5-year range
$85.0K / $2.8M
FY2021-FY2025
Trend
+10.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) returned to growth in FY2025 after 4 years of decline, reaching $94,000.
Based on SEC 10-K filings.
$94,000 in FY2025 with a 10-year CAGR of -31.1%.
Declined from $493,000 to $94,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -28.5%
- 10-Year CAGR
- -31.1%
Key checks
Key Insights
- 5-year CAGR of -28.5%, indicating a declining trend.
- In FY2025, pp&e (net) increased 10.6% year-over-year.
- Peak pp&e (net) was recorded in FY2018.
- Lowest pp&e (net) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $94.0K | +10.6% |
| FY2024 | $85.0K | -82.8% |
| FY2023 | $493.0K | -1.8% |
| FY2020 | $502.0K | -82.2% |
| FY2019 | $2.8M | -39.5% |
| FY2018 | $4.7M | +26.9% |
| FY2017 | $3.7M | +18.6% |
| FY2016 | $3.1M | -20.8% |
| FY2015 | $3.9M | +15.1% |
| FY2014 | $3.4M | +5.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026